Related Experiment Video
Updated: Jan 31, 2026

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
Published on: October 20, 2015
Identification of a novel chalcone derivative as ferroptosis inducer through targeting TrxR in prostate cancer
Jun Yan1, Long Cheng2, Qing-Qing Ma2
1The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510720, China; Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
Abstract:
Prostate cancer (PCa) remains a major threat to male health. Due to the inevitable progression of incurable castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT), it is an urgent need to seek out new therapeutic strategies that not dependent on androgen receptor (AR) signaling pathway. Through high-throughput screening of our in-house compound library, compound CD-15, a chalcone derivative, demonstrated remarkable anti-proliferative activity on AR-negative PCa cells at subnanomolar concentrations and completely blocked tumor growth in both cell line-derived xenograft (CDX) mice model and a zebrafish patient-derived xenograft (zPDX) model. Notably, CD-15 displayed a more favorable safety profile than the clinically widely-used drug docetaxel. Leveraging drug affinity responsive target stability (DARTS) technology and virtual target screening, thioredoxin reductase (TrxR) was identified as the direct target of CD-15. Our study also found TrxR was over-expressed in the serum and tissues in PCa patients and TrxR1 knockdown partially attenuated the suppressive effect of CD-15 in vitro and in vivo. Moreover, several means including BIAM assay, molecular docking, LC-MS/MS and DARTS analysis confirmed that CD-15 covalently modified selenocysteine 498 (U) residues within the redox-active site of TrxR, leading to the enzyme inhibition. Mechanistically, CD-15 exerted a dual anti-PCa mechanism, which was capable of inducing ferroptosis in a TrxR-dependent manner. Altogether, CD-15 emerges as a promising candidate for the treatment of PCa and deserves further investigation.
Insights
A novel chalcone derivative, CD-15, effectively inhibits prostate cancer (PCa) growth by targeting thioredoxin reductase (TrxR). This compound shows promise as a safe and effective therapy for castration-resistant prostate cancer (CRPC).
Area of Science:
- Oncology
- Drug Discovery
- Biochemistry
Background:
- Prostate cancer (PCa) progression to castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT) necessitates novel therapeutic strategies.
- Current treatments often rely on the androgen receptor (AR) signaling pathway, which becomes ineffective in CRPC.
Purpose of the Study:
- To identify and characterize novel therapeutic agents for PCa that are independent of the AR signaling pathway.
- To investigate the anti-cancer mechanisms and therapeutic potential of compound CD-15.
Main Methods:
- High-throughput screening of a compound library to identify anti-proliferative agents.
- In vivo studies using cell line-derived xenograft (CDX) and zebrafish patient-derived xenograft (zPDX) models.
- Drug affinity responsive target stability (DARTS) and virtual screening to identify the drug target.
- Biochemical assays (BIAM, LC-MS/MS, molecular docking) to confirm target engagement and mechanism of action.
Main Results:
- Compound CD-15, a chalcone derivative, demonstrated potent anti-proliferative activity against AR-negative PCa cells and inhibited tumor growth in vivo.
- Thioredoxin reductase (TrxR) was identified as the direct target of CD-15, with TrxR over-expression observed in PCa patients.
- CD-15 covalently binds to selenocysteine 498 in TrxR, inhibiting its activity and inducing ferroptosis, a TrxR-dependent anti-cancer mechanism.
- CD-15 exhibited a more favorable safety profile compared to docetaxel.
Conclusions:
- CD-15 is a promising therapeutic candidate for prostate cancer, particularly CRPC, due to its novel mechanism of action targeting TrxR.
- The dual anti-PCa mechanism involving ferroptosis induction highlights CD-15's potential for overcoming treatment resistance.
- Further investigation of CD-15 is warranted for its clinical development in prostate cancer treatment.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
07:21Establishment and Analysis of Three-Dimensional 3D Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts
Published on: February 3, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mechanisms of Retrovirus-induced Cancers
Measurement: Derived Units
Higher Derivatives
Methods of Classification and Identification
Derivatives